Article
Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis.
Digestive diseases and sciences - 1 Nov 2013
Juneja Manie, Euliano Rebekah, Satoskar Rohit, Lewis James H
Abstract excerpt
BACKGROUND AND AIMS: The protease inhibitors (PIs) boceprevir and telaprevir are currently standard treatment as part of triple therapy regimens (TTx) for chronic HCV genotype 1 (GT1) patients. In this preliminary analysis, we have compared demographic variables, polypharmacy, and Charlson's comorbid index (CCI) with Rapid Virological Response (RVR) and extended RVR (eRVR) rates in HCV GT1 patients receiving PI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.